|
Synonyms: SG-001 | SG001
enlonstobart is an approved drug
Compound class:
Antibody
Comment: Enlonstobart (SG001) is a fully humanised anti-PD-1 (PDCD1) monoclonal antibody. It was developed to treat advanced solid tumours by blocking the inhibitory the PD-1/PD-L1/L2 immune checkpoint.
|
| References |
|
1. Li G, Li X, Yin R, Feng M, Zuo J, Wei S, Kang S, Sun H, Li X, Wang Y et al.. (2024)
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer. Gynecol Oncol, 191: 165-171. [PMID:39447517] |
|
2. Shirley M. (2024)
Enlonstobart: First Approval. Drugs, 84 (12): 1659-1663. [PMID:39557797] |
|
3. Zuo J, Duan W, Zhao M, Chen Z, Lin J, Shi H, Jiang O, Zhang Y, Fang M, Wang L et al.. (2024)
Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial. Cancer Commun (Lond), 44 (9): 1042-1046. [PMID:39044367] |
